- Home
- UTHR vs EXEL Comparison
UTHR vs EXEL Comparison
Compare UTHR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- EXEL
- Stock Information
- Founded
- UTHR 1996
- EXEL 1994
- Country
- UTHR United States
- EXEL United States
- Employees
- UTHR N/A
- EXEL N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UTHR Health Care
- EXEL Health Care
- Exchange
- UTHR Nasdaq
- EXEL Nasdaq
- Market Cap
- UTHR 13.8B
- EXEL 10.4B
- IPO Year
- UTHR 1999
- EXEL 2000
- Fundamental
- Price
- UTHR $303.96
- EXEL $37.42
- Analyst Decision
- UTHR Buy
- EXEL Buy
- Analyst Count
- UTHR 13
- EXEL 21
- Target Price
- UTHR $382.00
- EXEL $43.65
- AVG Volume (30 Days)
- UTHR 694.7K
- EXEL 2.5M
- Earning Date
- UTHR 10-29-2025
- EXEL 10-28-2025
- Dividend Yield
- UTHR N/A
- EXEL N/A
- EPS Growth
- UTHR 17.94
- EXEL 81.76
- EPS
- UTHR 25.63
- EXEL 2.08
- Revenue
- UTHR $3,077,800,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- UTHR $13.89
- EXEL $9.24
- Revenue Next Year
- UTHR $5.68
- EXEL $13.04
- P/E Ratio
- UTHR $11.89
- EXEL $18.02
- Revenue Growth
- UTHR 17.62
- EXEL 10.73
- 52 Week Low
- UTHR $266.98
- EXEL $25.12
- 52 Week High
- UTHR $417.82
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- UTHR 52.97
- EXEL 39.69
- Support Level
- UTHR $302.19
- EXEL $37.71
- Resistance Level
- UTHR $312.44
- EXEL $38.95
- Average True Range (ATR)
- UTHR 6.59
- EXEL 0.80
- MACD
- UTHR -0.48
- EXEL 0.18
- Stochastic Oscillator
- UTHR 60.65
- EXEL 21.13
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.